Bispecific antibodies: Design, therapy, perspectives

Research output: Contribution to journalReview articlepeer-review

86 Citations (Scopus)

Abstract

Antibodies (Abs) containing two different antigen-binding sites in one molecule are called bispecific. Bispecific Abs (BsAbs) were first described in the 1960s, the first monoclonal BsAbs were generated in the 1980s by hybridoma technology, and the first article describing the therapeutic use of BsAbs was published in 1992, but the number of papers devoted to BsAbs has increased significantly in the last 10 years. Particular interest in BsAbs is due to their therapeutic use. In the last decade, two BsAbs – catumaxomab in 2009 and blinatumomab in 2014, were approved for therapeutic use. Papers published in recent years have been devoted to various methods of BsAb generation by genetic engineering and chemical conjugation, and describe preclinical and clinical trials of these drugs in a variety of diseases. This review considers diverse BsAb-production methods, describes features of therapeutic BsAbs approved for medical use, and summarizes the prospects of practical application of promising new BsAbs.

Original languageEnglish
Pages (from-to)195-208
Number of pages14
JournalDrug Design, Development and Therapy
Volume12
DOIs
Publication statusPublished - 22 Jan 2018

Keywords

  • Bispecific antibodies
  • Monoclonal antibodies
  • Therapeutic antibodies

Fingerprint Dive into the research topics of 'Bispecific antibodies: Design, therapy, perspectives'. Together they form a unique fingerprint.

Cite this